Conformational restriction of the pyrrolidine nitrogen in nicotine by the introduction of an ethylene bridge provided a potent and selective antagonist of the α4β2-subtype of the nicotinic acetylcholine receptors. Resolution by chiral SFC, pharmacological characterization of the two enantiomers, and determination of absolute configuration via enantioselective synthesis showed that the pharmacological activity resided almost exclusively in the (R)-enantiomer.KEYWORDS: Bridged-nicotine analogue, nAChRs, selective antagonist, Negishi cross-coupling reaction, oocyte T he neuronal nicotinic acetylcholine receptors (nAChRs) are members of the Cys-loop receptor family of ligandgated ion channels. They are assembled by either α-subunits or a combination of α-and β-subunits and play an important role in the peripheral and central nervous systems where they mediate neurotransmission in response to acetylcholine (ACh). 1,2 The involvement of nAChRs in a wide range of disease states as well as psychiatric and neurodegenerative disorders (such as depression, schizophrenia, attention deficit hyperactivity disorder, Alzheimer's and Parkinson's diseases, substance abuse, and pain) has made this class of receptors a highly pursued target for drug discovery. 3−6 Nicotine is the principal psychoactive ingredient in tobacco and acts as a potent agonist of the nAChRs. Structural modifications of nicotine have been the starting point for many drug discovery programs, and the introduction of conformational restraint as in compounds 1, 7,8 2, 9 and 3 10,11 has previously been investigated to probe the different possible conformations of nicotine (see Figure 1). Ligands 1 and 2 lock the pyrrolidine nitrogen in nicotine in the "down" position, whereas compound 3 locks it in the "up" position.In continuation of that line of thinking we recently reported the synthesis of new bridged-nicotine analogues locked in the "up" position, i.e., compounds rac-4 and rac-5. 12 Rigid nicotine analogue 1 was previously shown to be a selective partial agonist of rat α7 receptor, while 3 had no agonist activity at any nAChR of the investigated subtypes, whereas conformational restriction in 2 was reported to attenuate nicotinic activity.Herein we report the pharmacological characterization of the racemic compounds rac-4 and rac-5 at several nAChR subtypes. Furthermore, we describe the resolution of rac-4 by chiral supercritical fluid chromatography (SFC on chiral phase) and determination of absolute configuration of the most potent enantiomer via enantioselective synthesis.As depicted in Table 1, compound rac-5 exhibited low binding affinity at α4β2 nAChRs (K i = 13 μM), while its affinity for other nAChR subtypes was negligible. In contrast, the direct analogue of nicotine, rac-4, was a potent and highly subtype selective ligand for α4β2 receptors in terms of affinity. Compound rac-4 displayed nanomolar affinity (K i = 71 nM) toward the α4β2 nAChR with more than 100-fold selectivity over α4β4, α3β4, and α7 (K i values of 7.2, ∼100, and ∼50...